Active ingredientOmbitasvirCat. No. P-O021-001CAS 1258226-87-7Family · Pharmaceutical analytical standards
Ombitasvir
A direct-acting antiviral against hepatitis C: it inhibits NS5A, a protein the virus needs to replicate. It was approved in the United States in December 2014 and is used in combination with other antivirals for genotypes 1 and 4. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?In the regimen it is paired with ritonavir, born as an anti-HIV drug: here it is not used against the virus but only to slow the breakdown of paritaprevir, prolonging its effect.
Go to the active ingredient →Active ingredientOmbitasvirCat. No. P-O021-001CAS 1258226-87-7
Isotopically labelledOmbitasvir-d16Cat. No. P-O021-002
Isotopically labelledOmbitasvir-d6Cat. No. P-O021-003
ImpurityHydrolyzed OmbitasvirCat. No. P-O021-004No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.